Inflammation and apoptosis in relation with the effectiveness of bone marrow cell transplantation to patients with chronic heart failure

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 11, 2006, Pages 14-21

  Shumakov, V I ^a   Shevchenko, O P ^a   Orlova, O V ^a   Onischenko, N A ^a   Gureyev, S V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845494509     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Kannel W. B., Belanger A. J. Epidemiology of heart failure. Am. Heart J. 1991; 121: 951-957.
2. Assmus B., Schachinger V., Teupe C. et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction/ Circulation 2002; 106: 3009-3017.
3. Menasche P., Hagege A. A., Vilquin J. T. et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol. 2003; 41: 1078-1083.
4. Orlic D., Hill J. M., Arai A. E. Stem cell for myocardial regeneration. Cure. Res. 2002; 91: 1092-1102.
5. Dzau V. J., Gnecchi M., Pachori A. S. et al. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension 2005; 46: 7-10.
6. Badorff C., Brandes R. P., Popp R. et al. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation, 2003; 107: 1024-1032.
7. Baffour R., Zhou Y. F., Fuchs S. et al. Bone marrow-induced stimulation of endothelial and smooth muscle cell proliferation, migration, tube formation and production of growth factors. J. Am. Coll. Cardiol. 2001; 37: 232-236.
8. Hasper D., Hummel M., Kleber E. et al. Systemic inflammation in patients with heart failure. Eur. Heart J. 1998; 19: 761-765.
9. Murray D. R., Freeman G. L. Proinflammatory cytokines predictors of a failing heart? Circulation 2003; 107: 1460-1462.
10. Anand I. S., Latini R., Florel R. et al. C-reactive protein in heart failure. Circulation 2005; 112: 1428-1434.
11. Li S. H., Szmitko P. E., Weisel R. D. et al. C-reactive protein upregulates complement-inhibitory in endothelial cells. Circulation 2004; 109: 833-836.
12. Pasceri V., Willerson J. T., Yeh E. T. et al. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
13. Berendes E., Schmidt C., Van Aken H. et al. A-type and B-type natriuretic peptides in cardiac surgical procedures. Anesth. Analg. 2004; 98: 11-19.
14. Schnabel R., Rupprecht H. J., Lackner K. J. et al. Analysis of N-terminal-probrain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: result from the Atherogene study. Eur. Heart J. 2005; 26: 241-249.
15. Maeda K., Tsutamoto T., Wada A. et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end diastolic pressure in patients with symptomatic left ventricular dysfunction. Am. Heart J. 1998; 135: 825-832.
16. Bauriedel G., Hutter R., Becher H. et al. Evaluation of apoptosis in endomyocardial biopsies from patients with heart failure. Eur. Heart J. 1998; 19: 4468-4471.
17. Cook S. A., Poole-Wilson P. A. Cardiac myocyte apoptosis. Eur. Heart J. 1999; 20: 1619-1629.
18. Yamaguchi S., Yamaoka M., Okuyama M. et al. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am. J. Cardiol. 1999; 83: 1500-1503.
19. Nishigaki K., Minatoguchi S., Seishima M. et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J. Am. Coll. Cardiol. 1997; 29 (6): 1214-1220.
20. Kipshidze N. N., Serruys P. W. Handbook of cardiovascular cell transplantation. London: Martin Dunitz; 2004.
21. Verma S., Wang C. H., Li S. H. et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-919.
22. Mir M., Sola S., Tandon N. et al. Statin therapy improves indices of left ventricular function and serum markers of inflammation in normolipidemic patients with chronic heart failure. Eur. Heart. J. 2005; 26: 145-150.